RBC reiterates Alexza at outperform

Alexza Pharmaceuticals, Inc. was reiterated at outperform, above average risk, by RBC Capital Markets analyst Michael Yee after the company reported its third-quarter results and updated the status of its pipeline. According to the analyst, Alexza expects to sign a partnership agreement by year-end 2006 and "significant news flow" from its four clinical programs is expected in 2007. Shares of the Palo Alto, Calif.-based development-stage company were up 9 cents, or 1.10%, at $8.29. (Nasdaq: ALXA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.